Latest & greatest articles for depression

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on depression or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on depression and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for depression

21. Effects of selective serotonin reuptake inhibitors for postpartum depression: a meta-analysis of randomized controlled trials

Effects of selective serotonin reuptake inhibitors for postpartum depression: a meta-analysis of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2020 PROSPERO

22. A systematic review and meta-analysis on the effectiveness of stepped care treatment models for depressive and anxiety disorders across lifespan

A systematic review and meta-analysis on the effectiveness of stepped care treatment models for depressive and anxiety disorders across lifespan Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2020 PROSPERO

23. A network meta-analysis of control conditions in psychotherapy trials for depression

A network meta-analysis of control conditions in psychotherapy trials for depression Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2020 PROSPERO

24. Effectiveness of an Interventional Package on the Level of Anxiety, Depression, and Fatigue among Patients with Cervical Cancer. Full Text available with Trip Pro

Effectiveness of an Interventional Package on the Level of Anxiety, Depression, and Fatigue among Patients with Cervical Cancer. To evaluate the effectiveness of interventional package on the level of anxiety, depression, and fatigue.The study was conducted in room no. 5, first floor, B Block, Department of Radiotherapy, Nehru Hospital, Postgraduate Institute of Medical Education and Research, Chandigarh Quasi experimental pretest-posttest design was used in the study. A total of 60 patients (...) receiving radiotherapy/chemotherapy were assigned in two groups of 30 each, through total enumeration sampling technique. The tools used for the study were Zung Anxiety Scale, Beck Depression inventory, and Fatigue Scale. The protocol used for the study includes the Jacobson's Progressive muscle relaxtion technique, counsling and home care techniques.Sociodemographic variables and clinical profile of participants in both groups were comparable. Interventional package significantly reduces the anxiety

2019 Asia-Pacific journal of oncology nursing Controlled trial quality: uncertain

25. Clinical Practice Guideline for the Treatment of Depression Across Three Age Cohorts

Clinical Practice Guideline for the Treatment of Depression Across Three Age Cohorts Running head: APA GUIDELINE FOR THE TREATMENT OF DEPRESSION i Clinical Practice Guideline for the Treatment of Depression Across Three Age Cohorts American Psychological Association Guideline Development Panel for the Treatment of Depressive Disorders Adopted as APA Policy Feb. 16, 2019 Author Notes Members of the Guideline Development Panel for the Treatment of Depressive Disorders were John R. McQuaid (chair (...) First Street, NE, Washington, DC 20002-4242. E-mail: cpg@apa.org. APA GUIDELINE FOR THE TREATMENT OF DEPRESSION ii Abstract The American Psychological Association (APA) developed this clinical practice guideline to provide recommendations for the treatment of depressive disorders (including major depression, subsyndromal depression, and persistent depressive disorder). It addresses three developmental cohorts: children and adolescents; general adults; and older adults (ages 60 and over). Ten

2019 American Psychological Association

26. Effect of Depression Screening After Acute Coronary Syndromes on Quality of Life: The CODIACS-QoL Randomized Clinical Trial (Abstract)

Effect of Depression Screening After Acute Coronary Syndromes on Quality of Life: The CODIACS-QoL Randomized Clinical Trial Patients with acute coronary syndrome (ACS) and elevated depressive symptoms are at increased risk for recurrent cardiovascular events and mortality, worse quality of life, and higher health care costs. These observational findings prompted multiple scientific panels to advise universal depression screening in survivors of ACS prior to evidence from randomized screening (...) trials.To determine whether systematically screening for depression in survivors of ACS improves quality of life and depression compared with usual care.A 3-group multisite randomized trial enrolled 1500 patients with ACS from 4 health care systems between November 1, 2013, and March 31, 2017, with follow-up ending July 31, 2018. Patients were eligible if they had been hospitalized for ACS in the previous 2 to 12 months and had no prior history of depression. All analyses were performed on an intention

2019 EvidenceUpdates

27. Efficacy and safety of anti-inflammatory agents for the treatment of major depressive disorder: a systematic review and meta-analysis of randomised controlled trials (Abstract)

Efficacy and safety of anti-inflammatory agents for the treatment of major depressive disorder: a systematic review and meta-analysis of randomised controlled trials To systematically review the efficacy and safety of anti-inflammatory agents for patients with major depressive disorders.We searched the literature to identify potentially relevant randomised controlled trials (RCTs) up to 1 January 2019. The primary outcome was efficacy, measured by mean changes in depression score from baseline (...) analysis. The overall analysis pooling from 26 of the RCTs suggested that anti-inflammatory agents reduced depressive symptoms (SMD -0.55, 95% CI -0.75 to -0.35, I2=71%) compared with placebo. Higher response (RR 1.52, 95% CI 1.30 to 1.79, I2=29%) and remission rates (RR 1.79, 95% CI 1.29 to 2.49, I2=41%) were seen in the group receiving anti-inflammatory agents than in those receiving placebo. Subgroup analysis showed a greater reduction in symptom severity in both the monotherapy and adjunctive

2019 EvidenceUpdates

28. Association of Pediatric Obesity Treatment, Including a Dietary Component, With Change in Depression and Anxiety: A Systematic Review and Meta-analysis (Abstract)

Association of Pediatric Obesity Treatment, Including a Dietary Component, With Change in Depression and Anxiety: A Systematic Review and Meta-analysis Children and adolescents with obesity are at higher risk of developing depression and anxiety, and adolescent dieting is a risk factor for the development of depression. Therefore, determining the psychological effect of obesity treatment interventions is important to consider.To investigate the association between obesity treatment (...) interventions, with a dietary component, and the change in symptoms of depression and anxiety in children and adolescents with overweight/obesity.Searches of MEDLINE, Embase, Cochrane Library, and PsychINFO were conducted from inception to August 2018. Hand searching of references was conducted to identify missing studies.Obesity treatment interventions, with a dietary component, conducted in children and adolescents (age <18 years) with overweight/obesity, and validated assessment of depression

2019 EvidenceUpdates

29. Interest in participation of the development of a core outcome set for treatment of perinatal depression

Interest in participation of the development of a core outcome set for treatment of perinatal depression Interest in participation of the development of a core outcome set for treatment of perinatal depression We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Swedish Agency for Health Technology Assessment and Assessment of Social Services Interest in participation of the development of a core outcome set for treatment (...) of perinatal depression Share: Reading time approx. 4 minutes SBU is developing a Core Outcome Set on treatment of perinatal depression and we would like your help! Perinatal depression is depression experienced during pregnancy (known as ante or prenatal depression) or after childbirth (known as postnatal depression). A more detailed description of the project is available in the . This project has been registered in the A Core Outcome Set (COS) is an agreed minimum set of outcomes or outcome measures

2019 Swedish Council on Technology Assessement

30. Internet-Delivered Cognitive Behavioural Therapy for Major Depressive Disorder and Anxiety Disorders: A Health Technology Assessment

Internet-Delivered Cognitive Behavioural Therapy for Major Depressive Disorder and Anxiety Disorders: A Health Technology Assessment Internet-Delivered Cognitive Behavioural Therapy for Major Depressive Disorder and Anxiety Disorders: A Health Technology Assessment | CADTH.ca Find the information you need Internet-Delivered Cognitive Behavioural Therapy for Major Depressive Disorder and Anxiety Disorders: A Health Technology Assessment Internet-Delivered Cognitive Behavioural Therapy for Major (...) Depressive Disorder and Anxiety Disorders: A Health Technology Assessment Last updated: March 19, 2019 Project Number: OP0534-000 Product Line: Research Type: Device Result type: Report Major depressive disorder (MDD) is the occurrence of one or more major depressive episodes that last at least two weeks. Anxiety disorders include a range of conditions, including generalized anxiety disorder, panic disorder, and social anxiety disorder. MDD and anxiety disorders may be treated with pharmacological

2019 CADTH - Optimal Use

31. Esketamine for Treatment-Resistant Depression

Esketamine for Treatment-Resistant Depression Esketamine for Treatment-Resistant Depression | CADTH.ca CADTH Document Viewer Esketamine for Treatment-Resistant Depression Table of Contents Search this document Esketamine for Treatment-Resistant Depression April 2019 Summary Major depressive disorder (MDD) is a common, debilitating, and recurrent mental health disorder. Approximately 10% to 30% of patients with MDD will not reach complete clinical remission despite multiple antidepressant (...) pharmacologic approaches — this subpopulation is described as having treatment-resistant depression (TRD). TRD is a more challenging depressive disorder to treat and available therapies are often limited by significant psychological and physiological side effects. Esketamine is the S-enantiomer of racemic ketamine and is being developed as a nasal spray device for potential therapeutic use in patients with TRD. It has not yet been approved in any country but is under priority review at Health Canada

2019 CADTH - Issues in Emerging Health Technologies

32. Bright Light Therapy for Depression: Clinical Effectiveness

Bright Light Therapy for Depression: Clinical Effectiveness Bright Light Therapy for Depression: Clinical Effectiveness | CADTH.ca Find the information you need Bright Light Therapy for Depression: Clinical Effectiveness Bright Light Therapy for Depression: Clinical Effectiveness Last updated: August 28, 2019 Project Number: RB1391-000 Product Line: Research Type: Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness of bright (...) light therapy in patients with major depressive disorder or persistent depressive disorder? Key Message One systematic review, and two randomized controlled trials were identified regarding the clinical effectiveness of bright light therapy in patients with major depressive disorder or persistent depressive disorder. Files Rapid Response Summary of Abstracts Published : August 28, 2019 Related Content Follow us: © 2019 Canadian Agency for Drugs and Technologies in Health Get our newsletter:

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

33. Screening for depression

Screening for depression 1 Translation of the key statement of the final report S16-05 Screening auf Depression (Version 1.0; Status: 27 July 2018). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Extract IQWiG Reports – Commission No. S16-05 Screening for depression 1 Extract of final report S16-05 Version 1.0 Screening (...) for depression 27 July 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Screening for depression Commissioning agency: Federal Joint Committee Commission awarded on: 27 April 2016 Internal Commission No.: S16-05 Address of publisher: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Im Mediapark 8 50670 Köln Germany Phone: +49 221 35685-0 Fax: +49 221 35685-1 E-mail: berichte@iqwig.de

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

34. Major Depressive Disorder – Focused Critical Appraisal of a Network Meta-Analysis

Major Depressive Disorder – Focused Critical Appraisal of a Network Meta-Analysis Major Depressive Disorder – Focused Critical Appraisal of a Network Meta-Analysis | CADTH.ca Find the information you need Major Depressive Disorder – Focused Critical Appraisal of a Network Meta-Analysis Major Depressive Disorder – Focused Critical Appraisal of a Network Meta-Analysis Last updated: June 11, 2019 Project Number: HE0022-000 Product Line: Technology Review Research Type: Drug Result type: Report (...) Expected Completion Date: October 28, 2019 Major depressive disorder (MDD) is a common, debilitating, and recurrent mental health disorder. Over the past decades, multiple classes of antidepressant drugs have been developed to treat this condition. The relative effectiveness and safety of antidepressants are uncertain. This project will review a recently published network meta-analysis featuring broad comparisons of several oral antidepressants for MDD. Implications for decision-making

2019 CADTH - Technology Review

35. Repetitive Transcranial Magnetic Stimulation for Patients with Depression: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines – An Update

Repetitive Transcranial Magnetic Stimulation for Patients with Depression: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines – An Update Repetitive Transcranial Magnetic Stimulation for Patients with Depression: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines – An Update | CADTH.ca Find the information you need Repetitive Transcranial Magnetic Stimulation for Patients with Depression: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines (...) – An Update Repetitive Transcranial Magnetic Stimulation for Patients with Depression: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines – An Update Last updated: June 28, 2019 Project Number: RC1142-000 Product Line: Research Type: Devices and Systems Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness and safety of repetitive transcranial magnetic stimulation for patients with treatment-resistant depression? What is the cost

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

36. A newly designed intensive caregiver education program reduces cognitive impairment, anxiety, and depression in patients with acute ischemic stroke. Full Text available with Trip Pro

A newly designed intensive caregiver education program reduces cognitive impairment, anxiety, and depression in patients with acute ischemic stroke. This study aimed to evaluate the effect of a newly designed intensive caregiver education program (ICEP) on reducing cognitive impairment, anxiety, and depression in acute ischemic stroke (AIS) patients. One hundred and ninety-six AIS patients were divided into ICEP group and Control group in a 1:1 ratio using blocked randomization method (...) . In the ICEP group, the caregivers received ICEP, while in the Control group caregivers received usual education and guidance. All patients received conventional rehabilitation treatment. Cognitive impairment (assessed by Mini Mental State Examination (MMSE) score and Montreal Cognitive Assessment (MoCA) score), anxiety (assessed by Hospital Anxiety and Depression Scale (HADS)-A score and Self-rating Anxiety Scale (SAS) score), and depression (assessed by HADS-D score and Self-rating Depression Scale (SDS

2019 Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas Controlled trial quality: uncertain

37. Trial of SAGE-217 in Patients with Major Depressive Disorder. Full Text available with Trip Pro

Trial of SAGE-217 in Patients with Major Depressive Disorder. Altered neurotransmission of γ-aminobutyric acid (GABA) has been implicated in the pathogenesis of depression. Whether SAGE-217, an oral, positive allosteric modulator of GABA type A receptors, is effective and safe for the treatment of major depressive disorder is unknown.In this double-blind, phase 2 trial, we enrolled patients with major depression and randomly assigned them in a 1:1 ratio to receive 30 mg of SAGE-217 or placebo (...) once daily. The primary end point was the change from baseline to day 15 in the score on the 17-item Hamilton Depression Rating Scale (HAM-D; scores range from 0 to 52, with higher scores indicating more severe depression). Secondary efficacy end points, which were assessed on days 2 through 8 and on days 15, 21, 28, 35, and 42, included changes from baseline in scores on additional depression and anxiety scales, a reduction from baseline of more than 50% in the HAM-D score, a HAM-D score of 7

2019 NEJM

38. Psychological interventions in reducing stress, depression and anxiety among parents of children and adolescents with developmental disabilities: A systematic review and meta-analysis (Abstract)

Psychological interventions in reducing stress, depression and anxiety among parents of children and adolescents with developmental disabilities: A systematic review and meta-analysis To evaluate the effectiveness of psychological interventions in reducing stress, depression and anxiety among parents of children and adolescents with developmental disabilities.A systematic review and a meta-analysis.Seven electronic databases (CINAHL, CENTRAL, EMBASE, ProQuest Dissertation and Theses, PsycINFO (...) -analysis found that psychological interventions significantly reduced parental stress at postintervention but not at 3-6 months' postintervention. Inconclusive evidence was found for the effectiveness of psychological interventions in reducing parental depression and anxiety.Psychological interventions appeared to reduce parental stress temporarily. Healthcare professionals can offer varied psychological interventions for parents to choose from. Policymakers can ease accessibility and affordability

2019 EvidenceUpdates

39. Effect of Continuing Olanzapine vs Placebo on Relapse Among Patients With Psychotic Depression in Remission: The STOP-PD II Randomized Clinical Trial. (Abstract)

Effect of Continuing Olanzapine vs Placebo on Relapse Among Patients With Psychotic Depression in Remission: The STOP-PD II Randomized Clinical Trial. Psychotic depression is a severely disabling and potentially lethal disorder. Little is known about the efficacy and tolerability of continuing antipsychotic medication for patients with psychotic depression in remission.To determine the clinical effects of continuing antipsychotic medication once an episode of psychotic depression has responded (...) to combination treatment with an antidepressant and antipsychotic agent.Thirty-six week randomized clinical trial conducted at 4 academic medical centers. Patients aged 18 years or older had an episode of psychotic depression acutely treated with sertraline plus olanzapine for up to 12 weeks and met criteria for remission of psychosis and remission or near-remission of depressive symptoms for 8 weeks before entering the clinical trial. The study was conducted from November 2011 to June 2017, and the final

2019 JAMA Controlled trial quality: predicted high

40. A meta-analysis of randomized controlled trials of laughter and humour interventions on depression, anxiety and sleep quality in adults (Abstract)

A meta-analysis of randomized controlled trials of laughter and humour interventions on depression, anxiety and sleep quality in adults To quantify the effect of laughter and humour interventions on depression, anxiety, and sleep quality in adults.A meta-analysis of randomized controlled trials.PubMed, Embase, PsycINFO, Web of Science, Cochrane Central Register of Controlled Trials, Chinese National Knowledge Infrastructure, Weipu, and Wanfang Data were searched from their inception up (...) to December 2018.The reporting of this meta-analytical review was conducted according to the guidelines of the Cochrane Collaboration. Two reviewers selected the studies, extracted the data, and evaluated the risk of bias (Cochrane Collaboration bias assessment tool) of the included papers independently.Ten studies comprising 814 participants were included. Meta-analysis showed that these interventions significantly decreased adults' depression, anxiety, and improved their sleep quality. The results

2019 EvidenceUpdates